Wells Fargo lowered the firm’s price target on Myriad Genetics (MYGN) to $6 from $6.50 and keeps an Equal Weight rating on the shares. The firm notes Q4 revenue/EBITDA came in ahead, while 2026 guidance was reiterated. Wells believes 2026 will mark a key year for execution on turnaround strategy and pipeline catalysts. Pending more progress on these fronts and visibility to improved growth and profitability, the firm remains on the sidelines.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Execution and Reimbursement Risks Undermine Myriad Genetics’ Growth Outlook, Justifying Sell Rating
- Balancing Emerging Growth Momentum and Ongoing Uncertainty: Justifying a Hold Amid Attractive Valuation
- Myriad Genetics sees Q1 revenue $200M-$203M, consensus $211.19M
- Myriad Genetics backs FY26 revenue view $860M-$880M, consensus $868.06M
- Myriad Genetics reports Q4 adjusted EPS 4c, consensus (2c)